OAM
MYGN icon

Oppenheimer Asset Management’s Myriad Genetics MYGN Stock Holding History

Oppenheimer Asset Management’s Portfolio MYGN Stock Details MYGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-40,311
Closed -$585K – 1169
2022
Q4 		$585K Sell
40,311
-8,374
-17% -$156K 0.01% 809
2022
Q3 		$929K Buy
48,685
+1,694
+4% +$38.9K 0.02% 673
2022
Q2 		$854K Sell
46,991
-2,986
-6% -$62K 0.01% 720
2022
Q1 		$1.26M Buy
49,977
+687
+1% +$17.6K 0.02% 673
2021
Q4 		$1.36M Sell
49,290
-1,329
-3% -$38.5K 0.02% 680
2021
Q3 		$1.63M Buy
50,619
+233
+0.5% +$7.74K 0.02% 596
2021
Q2 		$1.54M Sell
50,386
-11,283
-18% -$326K 0.02% 615
2021
Q1 		$1.88M Buy
61,669
+5,889
+11% +$167K 0.03% 531
2020
Q4 		$1.1M Buy
55,780
+8,866
+19% +$143K 0.02% 663
2020
Q3 		$612K Sell
46,914
-1,474
-3% -$18.7K 0.01% 764
2020
Q2 		$549K Sell
48,388
-1,279
-3% -$18.2K 0.01% 777
2020
Q1 		$711K Buy
49,667
+2,168
+5% +$45.8K 0.02% 645
2019
Q4 		$1.29M Sell
47,499
-4,111
-8% -$113K 0.03% 558
2019
Q3 		$1.48M Buy
+51,610
New +$1.5M 0.03% 490

Other funds holding MYGN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
GCM
Glenview Capital Management New York $3.98B AUM 20.52% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
EARNEST Partners
EARNEST Partners Atlanta, Georgia $24.3B AUM 34.41% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return

Oppenheimer Asset Management's MYGN Position: Q1 2023 in Review

Oppenheimer Asset Management sold out of Myriad Genetics (MYGN) in Q1 2023, closing a stake of 40,311 shares — an estimated $585K sold.

Oppenheimer Asset Management first reported a position in MYGN in Q3 2019 and held it in 14 quarters. The position peaked at $1.88M in Q1 2021. 190 funds tracked by Wall St. Rank hold MYGN as of Q1 2023.

  • Oppenheimer Asset Management reported no remaining Myriad Genetics position as of Q1 2023 after selling out during the quarter.
  • Oppenheimer Asset Management sold 40,311 Myriad Genetics shares in Q1 2023, an estimated $585K.
  • Oppenheimer Asset Management first reported a position in Myriad Genetics in Q3 2019 and held it in 14 quarters.
  • Oppenheimer Asset Management's Myriad Genetics position peaked at $1.88M in Q1 2021.
  • 190 funds tracked by Wall St. Rank held Myriad Genetics as of Q1 2023.

Based on Oppenheimer Asset Management's 13F filing for Q1 2023, filed 10 May 2023.